These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
241 related articles for article (PubMed ID: 9404706)
1. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium. Silverman LB; McLean TW; Gelber RD; Donnelly MJ; Gilliland DG; Tarbell NJ; Sallan SE Cancer; 1997 Dec; 80(12):2285-95. PubMed ID: 9404706 [TBL] [Abstract][Full Text] [Related]
2. Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report. Kaleita TA; Reaman GH; MacLean WE; Sather HN; Whitt JK Cancer; 1999 Apr; 85(8):1859-65. PubMed ID: 10223582 [TBL] [Abstract][Full Text] [Related]
3. Acute lymphoblastic leukemia in infants: a decade of experience in the Czech Republic. Jabali Y; Starý J; Hak J; Blazek B; Hrstkova H; Mihál V; Mydlil J; Timr P; Gajdos P Med Pediatr Oncol; 2000 Nov; 35(5):493-5. PubMed ID: 11070483 [No Abstract] [Full Text] [Related]
4. Superior outcome of infant acute myeloid leukemia with intensive chemotherapy: results of the Japan Infant Leukemia Study Group. Kawasaki H; Isoyama K; Eguchi M; Hibi S; Kinukawa N; Kosaka Y; Oda T; Oda M; Nishimura S; Imaizumi M; Okamura T; Hongo T; Okawa H; Mizutani S; Hayashi Y; Tsukimoto I; Kamada N; Ishii E Blood; 2001 Dec; 98(13):3589-94. PubMed ID: 11739161 [TBL] [Abstract][Full Text] [Related]
5. Risk-directed treatment of infant acute lymphoblastic leukaemia based on early assessment of MLL gene status: results of the Japan Infant Leukaemia Study (MLL96). Isoyama K; Eguchi M; Hibi S; Kinukawa N; Ohkawa H; Kawasaki H; Kosaka Y; Oda T; Oda M; Okamura T; Nishimura S; Hayashi Y; Mori T; Imaizumi M; Mizutani S; Tsukimoto I; Kamada N; Ishii E Br J Haematol; 2002 Sep; 118(4):999-1010. PubMed ID: 12199778 [TBL] [Abstract][Full Text] [Related]
6. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study. Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409 [TBL] [Abstract][Full Text] [Related]
7. Infant acute lymphoblastic leukemia with MLL gene rearrangements: outcome following intensive chemotherapy and hematopoietic stem cell transplantation. Kosaka Y; Koh K; Kinukawa N; Wakazono Y; Isoyama K; Oda T; Hayashi Y; Ohta S; Moritake H; Oda M; Nagatoshi Y; Kigasawa H; Ishida Y; Ohara A; Hanada R; Sako M; Sato T; Mizutani S; Horibe K; Ishii E Blood; 2004 Dec; 104(12):3527-34. PubMed ID: 15297313 [TBL] [Abstract][Full Text] [Related]
8. Molecular analysis of infant acute lymphoblastic leukemia: MLL gene rearrangement and reverse transcriptase-polymerase chain reaction for t(4; 11)(q21; q23). Hilden JM; Frestedt JL; Moore RO; Heerema NA; Arthur DC; Reaman GH; Kersey JH Blood; 1995 Nov; 86(10):3876-82. PubMed ID: 7579356 [TBL] [Abstract][Full Text] [Related]
9. Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study. Pieters R; De Lorenzo P; Ancliffe P; Aversa LA; Brethon B; Biondi A; Campbell M; Escherich G; Ferster A; Gardner RA; Kotecha RS; Lausen B; Li CK; Locatelli F; Attarbaschi A; Peters C; Rubnitz JE; Silverman LB; Stary J; Szczepanski T; Vora A; Schrappe M; Valsecchi MG J Clin Oncol; 2019 Sep; 37(25):2246-2256. PubMed ID: 31283407 [TBL] [Abstract][Full Text] [Related]
10. Wilms' tumour gene (wt1) expression at diagnosis has no prognostic relevance in childhood acute lymphoblastic leukaemia treated by an intensive chemotherapy protocol. Gaiger A; Linnerth B; Mann G; Schmid D; Heinze G; Tisljar K; Haas OA; Gadner H; Lion T Eur J Haematol; 1999 Aug; 63(2):86-93. PubMed ID: 10480287 [TBL] [Abstract][Full Text] [Related]
11. Augmented post-remission therapy for a minimal residual disease-defined high-risk subgroup of children and young people with clinical standard-risk and intermediate-risk acute lymphoblastic leukaemia (UKALL 2003): a randomised controlled trial. Vora A; Goulden N; Mitchell C; Hancock J; Hough R; Rowntree C; Moorman AV; Wade R Lancet Oncol; 2014 Jul; 15(8):809-18. PubMed ID: 24924991 [TBL] [Abstract][Full Text] [Related]
12. Case-control study suggests a favorable impact of TEL rearrangement in patients with B-lineage acute lymphoblastic leukemia treated with antimetabolite-based therapy: a Pediatric Oncology Group study. Rubnitz JE; Shuster JJ; Land VJ; Link MP; Pullen DJ; Camitta BM; Pui CH; Downing JR; Behm FG Blood; 1997 Feb; 89(4):1143-6. PubMed ID: 9028935 [TBL] [Abstract][Full Text] [Related]
13. A randomized phase-III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Berlin-Frankfurt-Münster Study Group. Welte K; Reiter A; Mempel K; Pfetsch M; Schwab G; Schrappe M; Riehm H Blood; 1996 Apr; 87(8):3143-50. PubMed ID: 8605328 [TBL] [Abstract][Full Text] [Related]
14. Determinants of outcome after intensified therapy of childhood lymphoblastic leukaemia: results from Medical Research Council United Kingdom acute lymphoblastic leukaemia XI protocol. Hann I; Vora A; Harrison G; Harrison C; Eden O; Hill F; Gibson B; Richards S; Br J Haematol; 2001 Apr; 113(1):103-14. PubMed ID: 11328289 [TBL] [Abstract][Full Text] [Related]
15. TEL-AML1 fusion identifies a subset of children with standard risk acute lymphoblastic leukemia who have an excellent prognosis when treated with therapy that includes a single delayed intensification. Maloney K; McGavran L; Murphy J; Odom L; Stork L; Wei Q; Hunger S Leukemia; 1999 Nov; 13(11):1708-12. PubMed ID: 10557042 [TBL] [Abstract][Full Text] [Related]
16. Long-term outcome of treatment with protocols AL841, AL851, and ALHR88 in children with acute lymphoblastic leukemia: results obtained by the Kyushu-Yamaguchi Children's Cancer Study Group. Matsuzaki A; Ishii E; Nagatoshi Y; Eguchi H; Koga H; Yanai F; Inada H; Nibu K; Tamai Y; Akiyoshi K; Nakayama H; Hara T; Take H; Miyazaki S; Okamura J Int J Hematol; 2001 Apr; 73(3):369-77. PubMed ID: 11345205 [TBL] [Abstract][Full Text] [Related]
18. Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. Sancho JM; Ribera JM; Xicoy B; Morgades M; Oriol A; Tormo M; del Potro E; Debén G; Abella E; Bethencourt C; Ortín X; Brunet S; Ortega-Rivas F; Novo A; López R; Hernández-Rivas JM; Sanz MA; Feliu E; Eur J Haematol; 2007 Feb; 78(2):102-10. PubMed ID: 17087744 [TBL] [Abstract][Full Text] [Related]
19. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. Barry E; DeAngelo DJ; Neuberg D; Stevenson K; Loh ML; Asselin BL; Barr RD; Clavell LA; Hurwitz CA; Moghrabi A; Samson Y; Schorin M; Cohen HJ; Sallan SE; Silverman LB J Clin Oncol; 2007 Mar; 25(7):813-9. PubMed ID: 17327603 [TBL] [Abstract][Full Text] [Related]
20. The long-term results of childhood acute lymphoblastic leukemia at two centers from Turkey: 15 years of experience with the ALL-BFM 95 protocol. Güneş AM; Oren H; Baytan B; Bengoa SY; Evim MS; Gözmen S; Tüfekçi O; Karapınar TH; Irken G Ann Hematol; 2014 Oct; 93(10):1677-84. PubMed ID: 24863691 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]